May 10th 2024
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
Enfortumab Vedotin Plus Pembrolizumab Yield Promising Results in Advanced Urothelial Carcinoma
July 26th 2022Results from cohort K of the phase 1b/2 KEYNOTE-869 trial showed improved responses for patients with advanced or metastatic urothelial carcinoma when treated with enfortumab vedotin-efjv plus pembrolizumab.
Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC
July 23rd 2022Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
Roger Li, MD, Provides In-Depth Description of CG0070 Mechanism of Action in Bladder Cancer
June 23rd 2022Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
Cabozantinib After Chemotherapy Yields Similar Efficacy Vs Placebo in Advanced Urothelial Carcinoma
June 4th 2022Results from the phase 2 ATLANTIS trial did not show a benefit of cabozantinib in patients with advanced urothelial carcinoma compared with the placebo, but the treatment appeared to be tolerable.
Recap: Clinical Practice Experience With Avelumab First-Line Maintenance in Urothelial Carcinoma
May 31st 2022Daniel Petrylak, MD, and Donald Barry Boyd, MD, MS, review a publication presenting use of avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma in real-world practice and discuss their own experiences with the regimen.
Emerging Data and Future Directions in UC
Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.
ASCO GU 2022 Updates: PARP Inhibitors in First-Line and Subsequent UC Settings
Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.
ASCO GU 2022 Updates: Antibody-Drug Conjugates
Guru Sonpavde, MD, introduces emerging antibody-drug conjugates for treating metastatic UC, and reviews recent ASCO GU 2022 data on these regimens.
ASCO GU 2022 Updates: Trials on Combination Immunotherapy versus Chemotherapy
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022.
Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC
The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.
Treatment Options After Progression on Frontline Maintenance Therapy
Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.
Maintenance Therapy Duration and Considerations for Treatment Interruption
Experts comment on the typical urothelial cancer maintenance therapy duration in their practice, and situations in which they might consider interrupting treatment while maintaining patient response.